The effect of tobramycin incorporated with bismuth-ethanedithiol loaded on niosomes on the quorum sensing and biofilm formation of Pseudomonas aeruginosa

Microbial Pathogenesis

Volumn 107, Issue , 2017, Pages 129-135

  Mahdiun, Faeze ^a   Mansouri, Shahla ^a   Khazaeli, Payam ^b   Mirzaei, Rasoul ^c  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

AHL; Biofilm; Bismuth ethanedithiol; Niosome; Pseudomonas aeruginosa; Tobramycin

Indexed keywords

BISMUTH DERIVATIVE; BISMUTH ETHANEDITHIOL; CHOLESTEROL; N ACYLHOMOSERINE LACTONE; NIOSOME; POLYSORBATE 40; SORBITAN PALMITATE; TOBRAMYCIN; UNCLASSIFIED DRUG; 1,2-ETHANEDITHIOL; ANTIINFECTIVE AGENT; BISMUTH; GAMMA BUTYROLACTONE; HOMOSERINE LACTONE; LIPOSOME; MERCAPTOETHANOL;

AGROBACTERIUM TUMEFACIENS; ARTICLE; BIOFILM; CONTROLLED STUDY; ENCAPSULATION; HYDRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARTICLE SIZE; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG COMBINATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

4-BUTYROLACTONE; AGROBACTERIUM TUMEFACIENS; ANTI-BACTERIAL AGENTS; BIOFILMS; BISMUTH; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; LIPOSOMES; MERCAPTOETHANOL; MICROBIAL SENSITIVITY TESTS; PARTICLE SIZE; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; TOBRAMYCIN;

EID: 85016236008     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2017.03.014     Document Type: Article

References (31)

1. [1] Wagner, V.E., Iglewski, B.H., Pseudomonas aeruginosa biofilms in CF infection. Clin. Rev. allergy & Immunol. 35:3 (2008), 124–134.
2. [2] Parsek, M.R., Greenberg, E., Sociomicrobiology: the connections between quorum sensing and biofilms. Trends Microbiol. 13:1 (2005), 27–33.
3. [3] Mulcahy, H., Charron-Mazenod, L., Lewenza, S., Extracellular DNA chelates cations and induces antibiotic resistance in Pseudomonas aeruginosa biofilms. PLoS Pathog., 4(11), 2008, e1000213.
4. [4] Donlan, R.M., Costerton, J.W., Survival mechanismsof clinically relevant microorganisms. Clin. Microbiol. Rev. 15:2 (2002), 167–193.
5. [5] Tre-Hardy, M., Vanderbist, F., Traore, H., Devleeschouwer, M.J., In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures. Int. J. Antimicrob. agents 31:4 (2008), 329–336.
6. [6] Abdi-Ali, A., Mohammadi-Mehr, M., Alaei, Y.A., Bactericidal activity of various antibiotics against biofilm-producing Pseudomonas aeruginosa. Int. J. Antimicrob. agents 27:3 (2006), 196–200.
7. [7] Domenico, P., Baldassarri, L., Schoch, P.E., Kaehler, K., Sasatsu, M., Cunha, B.A., Activities of bismuth thiols against staphylococci and staphylococcal biofilms. Antimicrob. agents Chemother. 45:5 (2001), 1417–1421.
8. [8] Huang, C.-T., Stewart, P.S., Reduction of polysaccharide production in Pseudomonas aeruginosa biofilms by bismuth dimercaprol (BisBAL) treatment. J. Antimicrob. Chemother. 44:5 (1999), 601–605.
9. [9] Maki, D.G., Cobb, L., Garman, J.K., Shapiro, J.M., Ringer, M., Helgerson, R.B., An attachable silver-impregnated cuff for prevention of infection with central venous catheters: a prospective randomized multicenter trial. Am. J. Med. 85:3 (1988), 307–314.
10. [10] Sio, C.F., Otten, L.G., Cool, R.H., Diggle, S.P., Braun, P.G., Bos, R., et al. Quorum quenching by an N-acyl-homoserine lactone acylase from Pseudomonas aeruginosa PAO1. Infect. Immun. 74:3 (2006), 1673–1682.
11. [11] O'Loughlin, C.T., Miller, L.C., Siryaporn, A., Drescher, K., Semmelhack, M.F., Bassler, B.L., A quorum-sensing inhibitor blocks Pseudomonas aeruginosa virulence and biofilm formation. Proc. Natl. Acad. Sci. 110:44 (2013), 17981–17986.
12. [12] Tiwari, G., Tiwari, R., Sriwastawa, B., Bhati, L., Pandey, S., Pandey, P., et al. Drug delivery systems: an updated review. Int. J. Pharm. investigation, 2(1), 2012, 2.
13. [13] Ruckmani, K., Sankar, V., Sivakumar, M., Tissue distribution, pharmacokinetics and stability studies of zidovudine delivered by niosomes and proniosomes. J. Biomed. Nanotechnol. 6:1 (2010), 43–51.
14. [14] Ceren Ertekin, Z., Sezgin Bayindir, Z., Yuksel, N., Stability studies on piroxicam encapsulated niosomes. Curr. drug Deliv. 12:2 (2015), 192–199.
15. [15] Uchegbu, I.F., Florence, A.T., Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv. colloid interface Sci. 58:1 (1995), 1–55.
16. [16] Salerno, C., Chiappetta, D.A., Monteagudo, E., Bregni, C., Influence of surfactant structure in the encapsulation and stability of amphotericin B in niosomes. Lat. Am. J. Pharm. 30:9 (2011), 1728–1736.
17. [17] Mehta, S.K., Jindal, N., Kaur, G., Quantitative investigation, stability and in vitro release studies of anti-TB drugs in Triton niosomes. Colloids Surfaces B Biointerfaces 87:1 (2011), 173–179.
18. [18] Halwani, M., Hebert, S., Suntres, Z.E., Lafrenie, R.M., Azghani, A.O., Omri, A., Bismuth–thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa. Int. J. Pharm. 373:1 (2009), 141–146.
19. [19] Alhariri, M., Omri, A., Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection. Antimicrob. agents Chemother. 57:1 (2013), 569–578.
20. [20] Abdelaziz, A.A., Elbanna, T.E., Sonbol, F.I., Gamaleldin, N.M., El Maghraby, G.M., Optimization of niosomes for enhanced antibacterial activity and reduced bacterial resistance: in vitro and in vivo evaluation. Expert Opin. drug Deliv. 12:2 (2015), 163–180.
21. [21] Clinical, Institute LS. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard M7-a7, 2006, Clinical and Laboratory Standards Institute, Wayne, PA, USA.
22. [22] O'Toole, G.A., Microtiter dish biofilm formation assay. JoVE J. Vis. Exp.(47), 2011 e2437-e.
23. [23] Balaji, K., Thenmozhi, R., Pandian, S.K., Effect of subinhibitory concentrations of fluoroquinolones on biofilm production by clinical isolates of Streptococcus pyogenes. Indian J. Med. Res., 137(5), 2013, 963.
24. [24] Arora, S., Prashar, B., Dhamija hitesh, H., Chandel, A., Thakur, V., Niosomes: the unique vesicular drug carriers. J. Drug Deliv. Ther., 2(1), 2012 2250–1177.
25. [25] Domenico, P., Reich, J., Madonia, W., Cunha, B.A., Resistance to bismuth among Gram-negative bacteria is dependent upon iron and its uptake. J. Antimicrob. Chemother. 38:6 (1996), 1031–1040.
26. [26] Wu, C.-L., Domenico, P., Hassett, D.J., Beveridge, T.J., Hauser, A.R., Kazzaz, J.A., Subinhibitory bismuth-thiols reduce virulence of Pseudomonasaeruginosa. Am. J. Respir. Cell Mol. Biol. 26:6 (2002), 731–738.
27. [27] Varposhti, M., Ali, A.A., Mohammadi, P., Synergistic effects of bismuth thiols and various antibiotics against Pseudomonas aeruginosa biofilm. Jundishapur J. Microbiol., 7(3), 2014, e9142.
28. [28] Halwani, M., Blomme, S., Suntres, Z.E., Alipour, M., Azghani, A.O., Kumar, A., et al. Liposomal bismuth-ethanedithiol formulation enhances antimicrobial activity of tobramycin. Int. J. Pharm. 358:1 (2008), 278–284.
29. [29] Alipour, M., Suntres, Z.E., Lafrenie, R.M., Omri, A., Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by co-encapsulation of bismuth–ethanedithiol with tobramycin in liposomes. J. Antimicrob. Chemother. 65:4 (2010), 684–693.
30. [30] Zhu, J., Chai, Y., Zhong, Z., Li, S., Winans, S.C., Agrobacterium bioassay strain for ultrasensitive detection of N-acylhomoserine lactone-type quorum-sensing molecules: detection of autoinducers in Mesorhizobium huakuii. Appl. Environ. Microbiol. 69:11 (2003), 6949–6953.
31. [31] Zhu, J., Beaber, J.W., More, M.I., Fuqua, C., Eberhard, A., Winans, S.C., Analogs of the autoinducer 3-oxooctanoyl-homoserine lactone strongly inhibit activity of the TraR protein of Agrobacterium tumefaciens. J. Bacteriol. 180:20 (1998), 5398–5405.